VISLISI trial, a prospective clinical study allowing identification of a new metalloprotease and putative virulence factor from Staphylococcus lugdunensis.

Date publication

décembre 2016

Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CIANFERANI Sarah , Pr MEYER Nicolas

Tous les auteurs :
Argemi X, Prévost G, Riegel P, Keller D, Meyer N, Baldeyrou M, Douiri N, Lefebvre N, Meghit K, Ronde Oustau C, Christmann D, Cianférani S, Strub JM, Hansmann Y

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28017792

Résumé

Staphylococcus lugdunensis is a coagulase-negative staphylococcus that displays an unusually high virulence rate close to that of Staphylococcus aureus. It also shares phenotypic properties with S. aureus and several studies found putative virulence factors. The objective of the study was to describe the clinical manifestations of S. lugdunensis infections and investigate putative virulence factors.

Référence

Clin. Microbiol. Infect.. 2016 Dec;: